1 A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates 2 with poor survival in breast cancer

3 Mariska Miranda¹, Jodi M. Saunus², Seçkin Akgül¹, Mahdi Moradi Marjaneh^{1,3},
4 Jamie R. Kutasovic², Wei Shi¹, Oishee Chatterjee^{1,4}, Francesco Casciello¹, Esdy Rozali¹,
5 Herlina Y. Handoko¹, Adrian P. Wiegman¹, Tianqing Liu¹, Jason S. Lee¹, Bryan W. Day¹,
6 Stacey L. Edwards^{1,4}, Juliet D. French¹, Amy E. McCart Reed², Georgia Chenevix-Trench¹,
7 Kum Kum Khanna¹, Peter T. Simpson², Sunil R. Lakhani^{2,5} and Fares Al-Ejeh^{1,4,6} *

8 ¹ Cancer Program, QIMR Berghofer Medical Research Institute, Herston, Australia

9 ² UQ Centre for Clinical Research, The University of Queensland, Herston, Australia

10 ³ Currently at Department of Infectious Disease, Imperial College London, London, UK

11 ⁴ Faculty of Medicine, University of Queensland, St Lucia QLD 4072, Australia

12 ⁵ Pathology Queensland, The Royal Brisbane & Women's Hospital, Herston, Australia

13 ⁶ Currently at the Qatar Biomedical Research Institute, Doha, Qatar

14 * Correspondence: FAIEjeh@hbku.edu.qa; Tel.: +974 311 87 870

15 **Abstract**

16 **Background:** The nucleocytoplasmic shuttling of ERK5 has gained recent attention as a
17 regulator of its diverse roles in cancer progression but the exact mechanisms for this shuttling
18 are still under investigation.

19 **Methods:** Using *in vitro*, *in vivo* and *in silico* studies, we investigated the roles of shorter ERK5
20 isoforms in regulating the nucleocytoplasmic shuttling of active phosphorylated-ERK5 (pERK5).
21 Retrospective cohorts of primary and metastatic breast cancer cases were used to evaluate the
22 association of the subcellular localization of pERK5 with clinicopathological features.

23 **Results:** Extranuclear localization of pERK5 was observed during cell migration *in vitro* and at
24 the invasive fronts of metastatic tumors *in vivo*. The nuclear and extranuclear cell fractions
25 contained different isoforms of pERK5, which are encoded by splice variants expressed in breast
26 and other cancers in the TCGA data. One isoform, isoform-3, lacks the C-terminal
27 transcriptional domain and the nuclear localization signal. The co-expression of isoform-3 and
28 full-length *ERK5* associated with high epithelial-to-mesenchymal transition (EMT) and poor
29 patient survival. Experimentally, expressing isoform-3 with full-length ERK5 in breast cancer
30 cells increased cell migration, drove EMT and led to tamoxifen resistance. In breast cancer
31 patient samples, pERK5 showed variable subcellular localizations where its extranuclear
32 localization associated with aggressive clinicopathological features, metastasis, and poor
33 survival.

34 **Conclusion:** Our studies support a model of ERK5 nucleocytoplasmic shuttling driven by splice
35 variants in an interplay between mesenchymal and epithelial states during metastasis. Using
36 ERK5 as a biomarker and a therapeutic target should account for its splicing and
37 context-dependent biological functions.

38 **Keywords**

39 ERK5, ERK5 isoforms, nucleocytoplasmic shuttling, metastasis, epithelial-mesenchymal
40 transition.

41 Graphical Abstract

42

43 ERK5 isoform-3 expression deploys active ERK5 (pERK5) outside the nucleus to facilitate EMT
 44 and cell migration. In cells dominantly expressing isoform-1, pERK5 shuttles to the nucleus to
 45 drive cell expansion.

46 Background

47 ERK5, also known as the big mitogen kinase 1 (BMK1) or MAPK7, is activated via the upstream
 48 kinase MEK5 by various exogenous stimuli, including growth factors, cytokines and local
 49 stresses. Mechanistically, it regulates processes involved in tumor growth, differentiation and
 50 microenvironmental adaptation, including adhesion, cytoskeleton organization, epithelial-
 51 to-mesenchymal transition (EMT) and cancer-associated inflammation [1-8]. ERK5 activation
 52 has been implicated in proliferation, metastasis and drug resistance in melanoma, colon,
 53 prostate, ovarian, pancreatic, liver and lung carcinomas [9-15]. We and others have shown that
 54 ERK5 transcript and protein are overexpressed in aggressive breast cancers (BC), particularly
 55 in triple-negative phenotype breast cancer (TNBC) [16-20]. The involvement of ERK5 in
 56 oncogenic processes across multiple cancer types has spurred interest in therapeutic strategies
 57 targeting ERK5 [21]. So far, it has been unclear how ERK5 achieves different oncogenic
 58 outcomes with such multifaceted roles as a convergent signal transducer.

59 In this study, we describe variable subcellular localizations of active phosphorylated-ERK5
 60 (pERK5) in BC patient samples, which associated with different clinicopathological features and
 61 patient survival. We found that the variable subcellular localization of pERK5 is regulated by
 62 shorter isoforms of ERK5 which are produced by splice variants expressed in breast and other
 63 cancers. The expression of one isoform in particular, isoform-3, increases the accumulation of
 64 pERK5 outside the nucleus and cell migration, and causes tamoxifen resistance. The expression
 65 of isoform-3 drives EMT *in vitro* and associates with high levels of EMT and poorer survival
 66 across several cancer types. Our studies suggest a model of pERK5 nucleocytoplasmic shuttling
 67 driven by isoform-3 during BC metastasis, which has implications on the use of ERK5 as a
 68 biomarker and a therapeutic target.

69 **Methods**

70 **Breast cancer cell culture**

71 Breast cancer cell lines were obtained from ATCC™, cultured as per their instructions and were
 72 tested for mycoplasma and authenticated using STR profiling. The 4T1.2 cell line was a gift from
 73 Dr Cameron Johnstone (Monash University, Melbourne, Australia). For genetic depletion studies,
 74 ERK5 was silenced with human or mouse shRNAs purchased as pre-cloned in the pLKO.1-puro
 75 plasmid (MISSION® shRNA, Sigma-Aldrich, St Louis, MO, USA). Control shRNAs in the same
 76 plasmid were also purchased (Sigma). The IDs for the ERK5 shRNAs used are:
 77 TRCN0000001356 and TRCN0000010262 for human, TRCN0000023236 and
 78 TRCN0000232396 for mouse. Stable cell lines with ERK5 knockdown were generated by
 79 selection with puromycin (Sigma) at a concentration of 1 µg/mL for MDA-MB-231 cells and
 80 10 µg/mL for 4T1.2 cells.

81 ***In vivo* models**

82 The animal ethics committee at QIMR Berghofer gave approval for mouse experiments in this
 83 study (QIMR Berghofer ethics #A1808-606M). For orthotopic models, female NOD/SCID or
 84 BALB/c nude mice at 5 weeks of age (Animal Resources Centre, Perth, Australia) were
 85 inoculated in the mammary fat-pads with MDA-MB-231 cells (5x10⁶ per fat pad) or 4T1.2 cells
 86 (1x10⁶ per fat pad) in 50 µL of 50:50 (v/v) PBS:Matrigel™ (BD Biosciences, San Jose, CA, USA).
 87 Tumor growth was measured twice weekly by caliper measurements and weekly bioluminescent
 88 imaging (125 mg/kg luciferin I.P.) with the Xenogen IVIS system (Perkin Elmer, Waltham, MA,
 89 USA). For spontaneous metastasis in the MDA-MB-231 and 4T1.2 models, tumors were
 90 resected from the mammary gland when they reached 250 mm³ or 150 mm³, respectively. After
 91 tumor resection, metastases were quantified using weekly bioluminescence imaging as
 92 described above. Metastases in the lungs were detected by Immunohistochemistry (IHC) using
 93 the anti-Vimentin (V9, DAKO; Santa Clara, CA, USA) mAb as per manufacturer instructions.
 94 Resected primary MDA-MB-231 tumors and matched lung metastases were subjected to IHC
 95 staining for active ERK5 (pERK5) using anti-pERK5 antibody (clone #3371, Cell Signaling) at
 96 1:100 dilution (approximately 2 µg/mL final concentration). Antigen retrieval was done using

0.01 M sodium citrate buffer pH 6.0 and heating at 125°C for 4 minutes, blocking used donkey serum, and detection using the MACH1 Detection Kit as per manufacturer instructions (Biocare Medical, Pacheco, CA, USA).

Immunoblotting, and Immunoprecipitation

Whole cell protein lysates were prepared in ice-cold RIPA lysis buffer (1% v/v Triton X-100; 0.5% v/v Sodium Deoxycholate; 0.1% SDS; 150 mM Tris, pH 7.6; 2 mM EDTA; 150 mM NaCl) supplemented with Roche cOmplete™ Protease Inhibitor Cocktail (Sigma). Lysis was carried out on cultured cells; no trypsinization was used as it affects ERK5 and its isoforms detection. Cell fractions were prepared using the Subcellular Protein Fractionation Kit according to manufacturer instructions (Thermo Fisher Scientific). Immunoblots were probed with different antibodies: #3371 anti-pERK5 (only works for immunoblotting after immunoprecipitation) and #3372 anti-ERK5 from Cell Signaling Technology (Danvers, MA, USA); clone 07-507 anti-pERK5 (Millipore); pERK1/2 (Cell Signaling); anti-γ-tubulin (Sigma), anti-Lamin B (Thermo Fisher Scientific). Membranes were developed using secondary antibody HRP conjugates (Sigma), visualized using ImageQuant LAS 500 (GE Healthcare, Chicago, IL, US) then quantified relatively to loading controls by optical density using ImageJ (V1.46d, NIH). For immunoprecipitation (IP) assays, lysates were incubated with Co-IP Dynabeads™ (Invitrogen) conjugated to anti-pERK5 antibody (Cell Signaling) or a rabbit IgG control (Merck Millipore) and used for IP as per manufacturer instructions (Invitrogen).

Immunofluorescence

For 2D cultures, cells (1×10^6) were seeded onto 18-mm glass coverslips coated with poly-L-Lysine (Sigma), then washed in PBS 48h later, fixed with cold 4% paraformaldehyde for 10 minutes at RT and permeabilized with 0.1% Triton X-100 for 15 minutes at room temperature (RT). Cells were blocked with 3% BSA in PBS, incubated at 4°C overnight with primary antibodies in PBS with 3% BSA: rabbit anti-pERK5 antibody (Cell Signaling) at 1:14 dilution (15 µg/mL) or 15 µg/mL rabbit IgG control (Merck Millipore), and mouse anti-α-tubulin (Sigma, clone DM1A at 1:500). Cells were then incubated with the appropriate Alexa Fluor-conjugated secondary antibodies (2 µg/mL) for 60 minutes at RT. Alexa Fluor™ 555 Phalloidin (Invitrogen)

for 1 hour at RT was used instead of anti- α -tubulin staining antibody in selected experiments as indicated. Stained cells were then washed, counterstained with 4',6'-diamidino-2-phenylindole (DAPI) and mounted for microscopy using the Zeiss 780-NLO Point Scanning Confocal microscope (Zeiss, Oberkochen, Germany). CellProfiler [22] (v2.2.0) was used to determine the extranuclear and nuclear pERK5 staining intensities. Briefly, segmentation of nuclei (based on DAPI) and cell boundaries (based on tubulin) was used to identify the cytoplasm (between the nuclei and cell boundary outlines). This segmentation was used to quantify the green fluorescence intensity for pERK5 in the cytoplasm/membrane and nucleus associated with each nucleus (DAPI), thus determining the ratio of extranuclear to nuclear pERK5 localization. For 3D cultures, spheroids were fixed with 4% paraformaldehyde (30 min at room temperature) in the microwells on day 14, washed with PBS without disturbing the spheroids, adding 2% agarose gel to seal, and processed into paraffin. Once embedded, samples were sectioned and immunostained with the standard Tyramide Signal Amplification (TSA) protocol (Perkin Elmer). Antibodies and conditions used are detailed in **Table S10**. Imaging was done using the Zeiss AxioSkop2 (Zeiss). CellProfiler was used to determine the fluorescence intensity of the detected proteins after segmentation of nuclei (based on DAPI) to identify each cell.

TCGA transcript specific expression analysis

The breast cancer TCGA RNA-seq data was mapped for expression of the 18 *ERK5* transcripts. Briefly, the raw sequencing data was obtained from Cancer Genomics Hub. We then mapped the data against GENCODE gene model (release 24) including 18 *ERK5* transcripts using STAR (version 2.4.2a) and quantified the expression using RSEM (version 1.2.25). The pan-cancer TCGA RNA-seq data (transcript expression RSEM-FPKM) was analyzed using the UCSC Xena platform (<http://xena.ucsc.edu/>) for the expression of the 18 *ERK5* transcripts. Briefly, the TCGA pan-cancer transcript expression RNA-seq (TOIL RSEM FPKM) data was loaded into the UCSC Xena platform and analyzed for all *ERK5* gene (MAPK7) transcripts (32 cancer types after excluding acute myeloid leukemia based on our focus on solid cancers).

Exogenous expression of three main ERK5 isoforms in MCF7 BC cells

ERK5 cDNAs were purchased from GenScript® (Nanjing, China) in pcDNA3.1(+) plasmids;

Isoform-1 (Clone ID: OHu26794 - Human MAPK7, NM_139033.2), Isoform-2 (Clone ID: OHu27354 - Human MAPK7, NM_139032.2), and Isoform-3 (custom clone based on Ensembl transcript ENST00000490660.2, sequence from ATG start at bp 10 to TGA stop at bp 1611). Utilizing a series of standard molecular cloning techniques including PCR, restriction digestion, ligation and plasmid isolation, the cDNA sequence of ERK5 isoforms were cloned into pLVX-Puro plasmid (Clontech Laboratories, Mountain View, CA, USA). Plasmids were sequenced to confirm the presence of correct cDNA sequences at the 3'-end of the CMV promoter (data not shown). Lentiviral particles were prepared from HEK293T transfected using Lipofectamine-3000® (Invitrogen) with plasmids (i.e. pLVX-ERK5-Iso1, pLVX-ERK5-Iso2, and pLVX-ERK5-Iso3). Supernatants were collected on days 3, 5 and 7, purified and concentrated using the PEG Virus Precipitation Kit (Abcam, Cambridge, UK). Stable MCF7 cell lines infected with the ERK5 cDNA lentiviral particles were generated by selection in medium containing puromycin at a concentration of 1 µg/mL (Sigma). PCR using primers (**Table S3**) specific for endogenous or ectopic ERK5 isoform-3 transcripts were used to differentiate isoform-3 expression in BC cells and confirm the expression of ERK5 isoforms cDNAs in MCF7 cells.

Cell migration and motility assays

Real time cell motility assays were carried out using the HoloMonitor® M4 system (PHI, Lund Sweden) as per manufacturer instructions; 25-28 cells were tracked over 48 hours. Real time migration assays were performed using the xCELLigence system (CIM-Plate®; ACEA Biosciences Inc., San Diego, CA, USA). To promote cell migration, 20% serum and 100 nM estradiol (E2) were used as a chemoattractant in the base of the CIM-Plates.

TGFβ-induced MCF7 model

For TGFβ induction, MCF7 cells were cultured in 2D in the absence or presence of 10 ng/mL human TGFβ (PeproTech®, Rocky Hill, NJ, USA) for 3 weeks where TGFβ was replenished every 2 days, and 1 hour before collection for subsequent use. Spheroids were prepared from control MCF7-EV or MCF7-Iso3 cells, without or with TGFβ induction, using microwell devices. The microwell devices, with well diameter of 600 µm, were made as previously described [23] and were equilibrated with cell culture medium for 30 min before cell seeding. Cells were seeded

181 at 2.5×10^5 per microwell and incubated for 14 days to enable the formation of dense multicellular
182 spheroids. Media was replenished every 2 days. Spheroid growth was monitored by
183 phase-contrast imaging on the EVOS XL Core Cell Imaging System (Thermo Fisher Scientific,
184 Waltham, MA, USA) on days 2, 7, 11 and 14 and sphere area was measured using ImageJ.
185 Spheroids were also collected on day 14 for subsequent assays.

186 **Tamoxifen dose-response assays**

187 In 2D assays, cells were seeded in 24-well plates (4×10^4 /well) then incubated for 72 hours in the
188 presence of tamoxifen (0-10 μ M, Sigma). Cell growth in the absence or presence of tamoxifen
189 was monitored (every 2 hours) using the IncuCyte Zoom live content imaging from Essen
190 Bioscience (MI, USA). Cell growth was measured by the IncuCyte analysis software. For 3D
191 assays, treatment with 10 μ M tamoxifen was initiated two days after forming spheroids and
192 tamoxifen was replenished every 2 days. Spheroid growth was monitored using phase-contrast
193 imaging as described earlier and size (area) was measured using ImageJ.

194 **Epithelial to Mesenchymal Transition (EMT) array and validation**

195 The EMT RT² Profiler PCR Arrays (PAHS-090Z, QIAGEN; Hilden, Germany) were used to
196 profile control (EV) and isoform-3 expressing MCF7 cells grown as 2D cultures in the absence
197 or presence of TGF β . Arrays were carried out in technical duplicates. Standard RT-PCR using
198 independent sets of Predesigned KiCqStart[®] SYBR[®] Green Primers (Sigma, **Table S11**) was
199 carried out for validation with independent biological replicates from 2D cultures (n = 2) or 3D
200 cultures (duplicates from 25 spheres per replicate). The EMT arrays and subsequent validations
201 were performed on ViiA7 RT-qPCR System (Invitrogen).

202 **Breast cancer cohorts and pERK5 staining**

203 Institutional and local hospital human research ethics committees approved the study (University
204 of Queensland ethics #2005000785 and the Royal Brisbane Women's and Children Hospital
205 ethics #2005/022). Informed consent was obtained for all studies on cancer tissues. BC Tissue
206 microarrays (TMAs) were stained with anti-pERK5 antibody (clone #3371). TMAs were
207 constructed from the follow-up cohort (Queensland Follow Up cohort, QFU cohort) and

208 metastatic breast cancer (MBC) cohorts as described previously [24-27] (**Tables S6-8**). Briefly,
 209 4 μ m sections on Superfrost Plus slides were dewaxed prior to heat antigen retrieval using
 210 0.01 M sodium citrate buffer pH 6.0 in Biocare Medical Decloaker (Biocare Medical) at 125°C for
 211 4 minutes. Endogenous peroxidases were blocked with 1% hydrogen peroxidase for 5 minutes,
 212 and non-specific background staining was blocked with Background Sniper (Biocare Medical) for
 213 10 minutes. Slides were incubated with anti-pERK5 antibody at 1:175 dilution (approximately
 214 1.2 μ g/mL final concentration) for 1 hour at RT, followed by 30 minutes with MACH1 Universal
 215 HRP-Polymer and detected using the MACH1 Detection Kit (Biocare Medical). Slides were
 216 counterstained with Mayer's Hematoxylin for 1 minute as per the standard protocol.

217 **Statistical Analysis**

218 All statistical analysis was performed using GraphPad Prism® (v.7, GraphPad Software). The
 219 types of tests performed are indicated in respective Figure legends.

220 Results

221 Subcellular localization of pERK5 during metastasis and cell migration

222 Consistent with previous reports [16, 19, 28], *ERK5* depletion via stable expression of shRNAs
 223 had no effect on primary tumor formation or growth but inhibited spontaneous metastasis in two
 224 TNBC models; the MDA-MB-231 (MDA231) human xenograft and the 4T1.2 syngeneic mouse
 225 models (**Figure S1A-C**). Immunohistochemistry against vimentin in the MDA231 model
 226 confirmed the lack of lung metastases from tumors with *ERK5* depletion (**Figure 1A**). To study
 227 the localization of signaling-active ERK5 (pERK5), defined by phosphorylation of the TEY motif
 228 on Thr218/Tyr220, we first evaluated the specificity of antibodies against pERK5. The specificity
 229 of the pERK5 antibody from Cell Signaling Technology (product #3371) was confirmed by
 230 immunoprecipitation (detailed in **Additional File 1**) and immunofluorescence assays using
 231 *ERK5*-depleted cells as positive controls (**Figure 1B**). Interestingly, pERK5 was predominantly
 232 detected in the cytoplasm and the membrane (extranuclear) in the invasive MDA231 and 4T1.2
 233 TNBC cells, whereas pERK5 was mainly nuclear in the less invasive estrogen receptor-positive
 234 (ER+) MCF7 cells (**Additional File 1**). In primary MDA231 tumors, we observed extranuclear
 235 pERK5 at the leading edge, while nuclear pERK5 predominated in the tumor interior and the
 236 spontaneous lung metastases (**Figure 1C**). We also observed a significant increase in
 237 extranuclear pERK5 in migrating MDA231 and 4T1.2 cells (**Figure 1D**), further suggesting a role
 238 of the subcellular localization of pERK5 in cancer cell migration and metastasis.

239 ERK5 splice variants are expressed and activated in breast cancer

240 During the validation of the antibodies against pERK5, we observed three protein bands that
 241 were detected by an anti-ERK5 antibody after immunoprecipitation with two different pERK5
 242 antibodies. These bands were also detected with anti-pERK5 antibody after immunoprecipitation
 243 with another anti-pERK5 antibody, but not with an anti-pERK1/2 antibody, confirming they are
 244 ERK5 proteins (**Additional File 1**). Interestingly, immunoblotting of extranuclear (cytoplasm and
 245 membrane) and nuclear fractions of MDA231 and 4T1.2 cells revealed that the three pERK5
 246 bands had different subcellular distribution (**Figure 2A**). Based on similarities to mouse ERK5
 247 isoforms [29, 30], the three bands we observed correspond to possible human ERK5 isoforms

248 which have not been previously characterized. The three isoforms include: isoform-1 (full-length
249 ERK5, Q13164-1) at ~115 kDa, isoform-2 (N-terminal truncated, Q13164-2) at ~100 kDa, and
250 isoform-3 (C-terminal truncated, Q13164-3) at ~60 kDa.

251 To further characterize the possible ERK5 isoforms and their phosphorylation, subcellular
252 fractions from MDA231 cells were used for immunoprecipitation (IP) with anti-pERK5 antibody
253 before immunoblotting (IB) with an antibody against total ERK5 protein. ERK5 isoform-1
254 (full-length) was mainly detected in the extranuclear fraction in the input, whereas pERK5
255 isoform-1 distributed equally in the extranuclear and nuclear fractions (**Figure 2B** IP lanes).
256 ERK5 isoform-3 was detected in the nuclear fraction (**Figure 2B** nuclear input), but its activated
257 form (pERK5 isoform-3) was mainly in the extranuclear fraction (**Figure 2B** extranuclear IP). It is
258 noteworthy that higher levels of phosphorylated isoform-3 than isoform-1 were detected by IP
259 and IB (**Figure 2A-B**), suggesting that isoform-3 is preferentially activated. This is in line with
260 previous biochemical studies which showed that gradual deletion of the C-terminal domain of
261 ERK5 facilitates its activation, and significantly enhances its kinase activity [31]. Isoform-2 was
262 weakly phosphorylated and present in the nuclear fraction (**Figure 2A-B**). We confirmed the
263 authenticity of the pERK5 isoforms by re-probing the same blots with an antibody against
264 pERK1/2 which did not detect pERK1/2 after pERK5 IP (**Figure 2B** IB: pERK1/2).

265 To explore the expression of ERK5 isoforms in BC, we mapped the eighteen human *ERK5*
266 transcript variants annotated in Ensembl in The Cancer Genome Atlas (TCGA) RNA-Seq data
267 (**Tables S1-S2**). Thirteen transcripts encoding short variants of *ERK5* had very low expression
268 in BC (average z-score < 0, **Figure S2**). The remaining 5 transcripts (**Figure 2C**) include: three
269 variants that differ in the 3'UTR and encode full-length, isoform-1 (Q13164-1, transcripts
270 *MAPK7-202*, *MAPK7-203* and *MAPK7-204*), a variant encoding the N-terminal truncated
271 isoform-2 (Q13164-2, transcript *MAPK7-201*) and an intron-retaining transcript that produces the
272 C-terminal truncated isoform-3 (Q13164-3, transcript *MAPK7-208*). These variants were
273 frequently expressed in BC (**Figure 2D**), particularly in the TN/basal-like BC (**Figure 2E**).

274 **ERK5 isoform-3 regulates the subcellular distribution of active pERK5**

275 Mouse ERK5 isoforms with N-terminal truncation, which are similar to the human ERK5
276 isoform-2, are localized in the cell nucleus [29]. The mouse ERK5 with C-terminal truncation
277 (ERK5-T), which is similar to the human ERK5 isoform-3, binds to itself and to the full length
278 mouse ERK5 but does not translocate to the nucleus upon activation, thus causing the retention
279 of active mouse ERK5 in the cytoplasm [30]. To test how each of the human isoforms may
280 modulate the subcellular localization of pERK5, we used the MCF7 cells as they express low
281 levels of endogenous isoforms 2 and 3 (**Figure 3A** and **Figure S3A-D**). Ectopic expression of
282 isoform-1 or isoform-3, but not isoform-2, increased extranuclear levels of pERK5 (**Figure 3B**).
283 Estradiol (E2) is an inducer of ERK5 phosphorylation and nuclear translocation of pERK5 in ER+
284 cells [32], so we tested its effects in the MCF7 cell lines. E2 treatment induced nuclear
286 translocation of pERK5 in isoforms 1 and 2, but not in isoform-3 expressing cells (**Figure 3B-C**,
287 **Figure S3E**), indicating that isoform-3 retains pERK5 outside the nucleus even in the presence
288 of E2. Isoform-3 promoted cell migration, motility and tamoxifen resistance in MCF7 cells
289 (**Figure 3D-F**, **Figure S3F**).

290 **Co-expression of ERK5 splice isoforms 1 and 3 associates with poor cancer survival**

291 Having found that proportionally high expression of isoform-3 promoted extranuclear ERK5
292 activity and led to an invasive phenotype, we investigated the potential clinical relevance of
293 ERK5 isoforms in solid cancers. The TCGA Pan-Cancer RNA-seq data from 32 solid cancer
294 types (n = 9,459 cases, **Table S4**) showed that all protein-coding isoforms were detectable
295 across the different cancer types (**Figure 4A**). Higher expression of isoform-1 and isoform-3, or
296 their combination associated with poor survival, whereas the expression of isoform-2 did not
297 associate with survival (**Figure 4B**). Higher co-expression of isoforms 1 and 3 associated with a
298 shift from an epithelial to a mesenchymal state (EMT score, **Figure 4C**), suggesting a role of this
299 co-expression in EMT (**Figure S4B**). Since high co-expression of isoforms 1 and 3 was detected
300 in most cancer types, the association of this co-expression with poorer survival and EMT was not
301 driven by bias in particular, poor prognosis cancer types (**Figure S4C**).

302 **Co-expression of ERK5 isoforms 1 and 3 drives epithelial-to-mesenchymal transition**

303 To test whether the co-expression of isoforms 1 and 3 of ERK5 can drive EMT *in vitro*, we used
 304 the MCF7-Iso3 cells which co-express ERK5 isoforms 1 and 3 as model and compared them to
 305 the MCF7-Empty vector (EV) cells that predominantly express endogenous isoform-1. Under
 306 basal and TGF β -induced conditions, isoform-3 expression led to higher extranuclear pERK5
 307 localization (**Figure 5A**). We profiled these cells using an 84-gene EMT panel (**Table S6** and
 308 **Figure S5A**; 73 genes showed expression; 11 genes were not detected). Overall, MCF7-Iso3
 309 overexpressing cells showed significant deregulation of this EMT gene-panel compared to
 310 MCF7-EV cells, without or with TGF β (**Table S6**). To investigate the clinical relevance of this *in*
 311 *vitro* profiling, we analyzed the association of the EMT gene-panel with the co-expression of
 312 isoforms 1 and 3 in the TCGA Pan-Cancer RNA-seq data. Of the 70 genes from the EMT panel
 313 which associated significantly with the co-expression of isoforms 1 and 3 in the TCGA data, 39
 314 genes (56%) were affected by the co-expression of isoform 1 and 3 in the MCF7-Iso3 cells with
 315 or without TGF β induction (**Figure S5B**). We selected 17 of these 39 genes for validation and
 316 found that 15 genes (88%) were indeed significantly regulated by the co-expression under basal
 317 or TGF β -induced conditions (**Figure 5B**). As EMT is implicated in tamoxifen resistance, we also
 318 tested the response of MCF7-EV and MCF7-Iso3 spheroids to tamoxifen. Both in the absence or
 319 presence of TGF β , MCF7-Iso3 spheroids showed significantly lower response to tamoxifen than
 320 MCF7-EV spheroids (**Figure 5C**). The MCF7-Iso3 spheroids showed a loss of membrane
 321 staining for epithelial cytokeratin 19 (CK19), E-cadherin and β -catenin, gained expression of
 322 basal cytokeratin 5 (CK5), and were enriched for SOX2 positive nuclei (**Figure 5D-E**). The
 323 MCF7-Iso3 spheroids, compared to MCF7-EV spheroids, had significantly higher mRNA levels
 324 of EMT-related transcription factors (*FOXC2*, *TWIST1*, and *SNAI2*) and extracellular matrix
 325 (ECM)-related genes (*SPARC*, *COL5A2* and *KRT14*) (**Figure S5C**).

326 **ERK5 activation and extranuclear localization is associated with poor patient survival**

327 The subcellular localization of pERK5 was investigated in a large cohort of primary breast
 328 tumors sampled in tissue microarrays (TMAs) with detailed clinicopathologic annotation,
 329 including survival outcomes up to 30 years post-diagnosis (the QFU cohort) [24-27]. pERK5 was

observed in the nucleus, membrane and cytoplasm of tumor cells (**Figure 6A, Tables S6-S7**). Membrane (M) and cytoplasmic (C) staining were highly correlated (Pearson correlation p-values = $8.2E-8$), so these scores were combined (MC, or extranuclear). Strong extranuclear staining (MC2) associated with poor patient survival irrespective of BC subtype or nuclear co-expression (**Figure 6B, Figure S6B**). Nuclear pERK5 staining (N) associated with favorable survival (**Figure 6C, Figure S6B**), particularly in ER+ cases (**Figure S6C**).

To further examine the clinical relevance of this distribution, and because the nuclear and extranuclear pERK5 staining were not mutually exclusive (**Figure S6D**), we categorized the QFU cases according to the relative 'doses' of nuclear and extranuclear pERK5. The consolidated patterns included negative extranuclear and nuclear staining (Category-A, Cat-A), positive nuclear staining without strong extranuclear staining (Category-B, Cat-B), strong nuclear staining without strong extranuclear staining (Category-C, Cat-C), and strongly positive for extranuclear pERK5 irrespective of nuclear staining. (Category-D, Cat-D). Tumors with abundant extranuclear pERK5 (Cat-D) were generally larger with high histological grade and more frequent lymph node metastases (**Figure 6D**) - hallmarks of aggressive clinical behavior. This category was enriched for HER2+ and TNBC cases, with frequent expression or markers of primitive, mesenchymal state (vimentin) and/or aggressive behavior [33, 34]. In contrast, nuclear pERK5 (Cat-C) was inversely associated with tumor size, lymph node metastasis and TNBC status.

We validated our findings in an independent metastatic breast cancer cohort (MBC; n = 285, **Table S9**) comprising 70 primary breast tumors and 215 metastases from brain, gynecological and other sites sampled in TMAs. Compared to the cross-sectional QFU cases, metastatic BC (MBC) tumors exhibited higher expression of pERK5 in all three cell compartments (**Figure S6E**). Nuclear pERK5 was significantly higher in metastases (**Figure 6E**). Extranuclear pERK5 was higher in MBC and metastases compared to cross-sectional QFU cases but was lower in metastases compared to their matching MBC (**Figure 6F**).

In summary, primary metastatic BC and metastases showed higher frequency of both Category-D (strong extranuclear pERK5) and Category-C (strong nuclear pERK5) cells compared to cross-sectional QFU cases (**Figure 6G**). These cell types also distributed differently at the metastatic sites compared to their matched primary tumors (**Figure 6G**), increased category-C and decreased category-D, suggesting that pERK5 is redistributed during metastatic colonization.

Discussion

This study found that human *ERK5* splice variants encoding short protein isoforms are expressed and are functional in cancer. Generic suppression of all isoforms inhibited metastasis in mouse models of BC. Higher expression of ERK5 isoform-3 promoted activation in the cytosol, drove EMT and cell migration; while dominant expression of full-length ERK5, isoform-1, favors nuclear activity and epithelial-like differentiation. In general, our study supports ongoing development of ERK5-targeting agents, but also underscores its regulatory and functional complexity, thus exemplifies how this could stifle preclinical or clinical approaches that fail to account for ERK5 isoform-specific effects.

The N-terminal half of ERK5 (kinase domain, residues 1-407) binds to its C-terminus (transcriptional domain, residues 407-806), closed conformation, for nuclear export and this interaction dissociates upon TEY motif phosphorylation, open conformation, leading to nuclear translocation [35]. Independent of their phosphorylation status, ERK5 molecules exists as oligomers via the oligomerization domain (residues 140- 406) [29]. A C-terminal deletion construct (residues 1-407), which lacks the nuclear localization signal and is similar to the naturally expressed isoform-3 (residues 1-553), localizes to both the nucleus and cytoplasm [35]. We found that isoform-3 localizes to the nucleus and cytoplasm, but the cytoplasmic pool was highly phosphorylated. The ERK5 C-terminus was shown to reduce the phosphorylation and kinase activity of its N-terminal half in a self-regulatory mechanism [31]. In agreement, we found high levels of phosphorylated isoform-3 in TNBC cells and was immunoprecipitated by anti-pERK5 antibody more efficiently than full-length ERK5.

Accumulating evidence [36] is challenging the classic linear model where ERK5 is simply translocated to nucleus upon activation by MEK5. Madak-Erdogan et al. [32] described that pERK5 is retained in the cytoplasm of ER- BC cells but shuttled to the nucleus in ER+ cells to drive ER-mediated transcription. This group also implicated nucleocytoplasmic transport machinery, particularly XPO1, in the extranuclear retention of pERK5 and tamoxifen resistance in ER+ cells. Inhibition of XPO1 redistributes pERK5 to the nucleus and restores tamoxifen sensitivity [37]. Our studies now clarify that this may occur in the context of proportionally high expression of isoform-3, a common context in several cancer types. Importantly, while nuclear localization of pERK5 was associated with ER positivity, our studies in BC cohorts showed that nuclear and extranuclear pERK5 are not mutually exclusive, and that a proportion of ER+ BC displayed extranuclear pERK5 staining. Extranuclear pERK5 associated with metastatic primary tumors and poorer survival irrespective of ER status.

Serendipitously, the previous biochemical studies [31] showing higher activating autophosphorylation and kinase activity of C-terminal deletion constructs of ERK5 may explain the pathogenic nature of the similar, naturally expressed isoform-3 of ERK5. Studies from murine cells suggested that regulation of ERK5 signaling may be mediated at the level of RNA processing which produce mouse ERK5 isoforms [29, 30], similar to the human isoforms in our study. Mouse ERK5-T, which is similar to human isoform-3, heterodimerizes with full-length mouse ERK5 irrespective of phosphorylation status, and inhibits nuclear translocation of pERK5 [30]. Again, biochemical studies found that unlike full-length human ERK5, a C-terminal deletion construct (residues 1-490) remains in a cytosolic complex with Cdc37-Hsp90 β even after ERK5 activation [38]. Here, we show that the balance of expressed *ERK5* splice variants is integral to the phenotypic and functional requirements of cancer cells during progression and metastasis. Expression of ERK5 isoform-3 in cancer associates with a mesenchymal state, metastasis and poor patient survival. Experimentally, we show that exogenous expression of isoform-3 facilitated cell migration and tamoxifen-resistance. These phenotypes were paralleled with extranuclear accumulation of pERK5 under unstimulated, estrogen- or TGF β -induced conditions. Mechanistically, the expression of isoform-3 induced EMT characterized by loss of epithelial

416 markers and gain of basal, mesenchymal markers. Isoform-3 increased the expression of
 417 EMT-related transcription factors and EMT/ECM-related genes, specifically the
 418 *SPARC-FOXC2-SNAI2-TWIST1* EMT-axis in 2D and 3D cell cultures. This axis was further
 419 upregulated in isoform-3 expressing cells under TGF β -induced conditions.

420 ERK5 promotes Src-induced podosome formation and cell invasion [2], interacts with actin
 421 organizing proteins fascin (within the Cdc37-Hsp90 β complex) [38] and cofilin [32], which are
 422 also associated with aggressive BC [39, 40], and is important for cell migration and metastasis
 423 as reported in our study and others [16, 19, 28, 32]. In contrast to these extranuclear activities,
 424 nuclear pERK5 drives a distinct functional program by promoting transcription of genes required
 425 for proliferation, while suppressing those involved in immunogenicity and apoptosis [32]. Our
 426 studies suggest a model that reconciles these findings, where alternative splicing maintains
 427 ERK5 localization and activation in dynamic equilibrium depending on requirements dictated by
 428 the microenvironment. For example, stimuli like hypoxia, growth factors or vascular sheer stress
 429 may exploit the activation-susceptible isoform-3, being in open conformation and without the
 430 self-regulatory C-terminus, or by promoting the expression of isoform-3, to facilitate invasion and
 440 migration. Once such stimuli wane, isoform-3 expression or phosphorylation levels regress, and
 441 nuclear functions are restored. This model may also resolve conflicting reports on the role of
 442 ERK5 in EMT [19, 28, 41-46], which have not addressed the distinctive expression or the
 443 contribution of isoform-3 to EMT. Importantly, our data will inform the development of rational
 444 therapeutic strategies targeting ERK5, allowing due consideration of its complex regulation,
 445 structure and context-dependent biological functions.

446 The results in this study and the model for a dynamic equilibrium of ERK5 localization and
 447 activation through its alternative splicing raise several biological and clinical questions for future
 448 studies. The molecular and the environmental queues that may modulate the expression of
 449 isoform-3, and the co-expression of isoform-3 with isoform-1 remain unknown. In addition to the
 450 association of increasing levels of isoforms 1 and 3 co-expression with increasing EMT scores
 451 and patient deaths, we should note that the highly metastatic 4T1.2 mouse cells express a
 452 higher ratio of phosphorylated isoform-3 to phosphorylated isoform-1 than the relatively less

metastatic MDA-MB-231 cells. Thus, further studies are needed to determine the relative expression of isoform-3 to isoform-1 that is required to drive metastasis *in vivo*. Similarly, whether the expression of isoform-3 alone, in the absence of full-length ERK5, can drive EMT and metastasis is worth further study. Moreover, while we characterized EMT-related markers, the exact mechanism behind the EMT changes driven by the exogenous expression of isoform-3 with endogenously expressed isoform-1 in MCF7 cells is unknown. The interaction of ERK5 with cytoskeletal reorganizing fascin [38] and cofilin [32] may be enhanced when isoform-3 is expressed. Since ERK5 exists as an oligomer, both in the inactive and active states, it will be important to compare homogenous oligomers of ERK5 (isoform-1 oligomers vs. isoform-3 oligomers) and heterogenous oligomers (isoform-1/isoform-3 oligomers) for their interactions with other cellular proteins. Different ERK5 oligomers may have different interactors and downstream effectors. Also relevant here is that isoform-3 lacks the C-terminal domain and it has been shown that C-terminal deletion constructs of ERK5 increases the activating autophosphorylation and activity of ERK5 [31]. We observed strong activation of isoform-3 compared to isoform-1 in MDA-MB-231 and 4T1.2 cells and immunoprecipitation of pERK5 in the isoform-3 form was more efficient. These observations have implications on the biology of ERK5 and raise the question if current ERK5 inhibitors are efficient against isoform-3 activation or its function.

Conclusion

We found that the subcellular distribution of signaling-active ERK5 protein (pERK5) associates with different clinical outcomes in breast cancer and is modulated by a shorter isoform of ERK5. Isoform-3 particularly is activated and retains active pERK5 outside the nucleus, which drives an aggressive mesenchymal state, cell migration and tamoxifen-resistance in breast cancer cells. The expression of isoform-3 of ERK5 in cancer patients associates with an aggressive mesenchymal state and poor patient survival. Our study elucidates that ERK5 targeting strategies should account for its splicing and context-dependent biological functions.

482 **Abbreviations**

483 3'UTR: three prime untranslated region
 484 BC: breast cancer
 485 DAPI: 4',6'-diamidino-2-phenylindole
 486 E2: estradiol
 487 EMT: epithelial-to-mesenchymal transition
 488 ER+: estrogen receptor-positive
 489 ERK1/2: extracellular-signal-regulated kinase 1/2
 490 pERK1/2: phosphorylated extracellular-signal-regulated kinase 1/2
 491 ERK5: extracellular-signal-regulated kinase 5
 492 pERK5: phosphorylated extracellular-signal-regulated kinase 5
 493 HRP: horseradish peroxidase
 494 IB: immunoblotting
 495 IF: immunofluorescence
 496 IHC: immunohistochemistry
 497 IP: immunoprecipitation
 498 kDa: kilo dalton
 499 MBC: metastatic breast cancer
 500 MEK5: mitogen-activated protein kinase kinase 5
 501 RNA-seq: RNA sequencing
 502 RT: room temperature
 503 RT-PCR: reverse transcription polymerase chain reaction
 504 shRNA: short hairpin RNA
 505 TCGA: the cancer genome atlas
 506 TEY: threonine-glutamate-tyrosine motif
 507 TGFβ: transforming growth factor beta
 508 TMAs: tissue microarrays
 509 TNBC: triple negative breast cancer
 510 TSA: tyramide signal amplification
 511 UCSC: University of California Santa Cruz

512 **Declarations**

513 **Ethics approval and consent to participate:** Institutional and local hospital human research
514 ethics committees approved the study (University of Queensland ethics #2005000785 and the
515 Royal Brisbane Women's and Children Hospital ethics #2005/022). Informed consent was
516 obtained for all studies on cancer tissues.

517 **Consent for publication:** Not applicable

518 **Availability of data and materials:** The datasets generated and analyzed in this study are
519 available in the supplementary tables.

520 **Competing interests:** The authors declare that they have no competing interests.

521 **Funding:** This research was funded by Rio Tinto Ride to Conquer Cancer, RTCC-WEWC15014
522 to F.A. and the Cancer Council Queensland, APP1106310 to F.A., P.T.S. and J.M.S. F.A. was
523 supported by Australian Research Council Fellowship (FT130101417). M.M., J.R.S., O.C.,
524 E.N.R. and H.Y.H. were supported by the Australian National Health and Medical Research
525 Council (NHMRC Grant APP1082458 to F.A.). M.M. was also supported by University of
526 Queensland tuition fee stipend during PhD studies (co-supervisors KK.K. and F.A.). Patient
527 cohorts were funded by NHMRC Program Grants, APP1017028 and APP1113867, to G.C.T.,
528 S.R.L. and KK.K. The APC was funded by Qatar Biomedical Research Institute.

529 **Authors' contributions:** Conceptualization: F.A. and M.M.; methodology: M.M., J.M.S, J.R.K.,
530 S.A. W.S., T.L., O.C., E.N.R. H.Y.H., A.P.W., M.M.M., F.C., and F.A.; software: M.M., J.M.S.,
531 J.R.K., M.M.M., J.D.F., S.L.E., W.S., F.C. and F.A.; validation: M.M. and F.A.; formal analysis:
532 F.A., M.M., J.M.S, J.R.K., A.E.MR., P.T.S., W.S., H.Y.H., A.P.W., F.C., J.S.L., O.C., E.N.R.,
533 M.M.M., J.D.F. and S.L.E.; investigation: M.M., J.M.S, J.R.K., S.A. W.S., O.C., E.N.R. H.Y.H.,
534 A.P.W., M.M.M., F.C., and F.A.; resources: F.A., J.M.S, J.R.K., A.E.MR., P.T.S., J.S.L., J.D.F.,
535 S.L.E., T.L., B.W.D, G.C.T, KK.K. and S.R.L.; data curation: M.M.M., J.D.F., S.L.E., J.M.S,
536 J.R.K., A.E.MR., P.T.S., S.R.L. and F.A.; writing – original draft: F.A., M.M. and J.M.S.;
537 writing—review and editing: all authors; visualization: M.M., J.M.S., and F.A.; supervision: F.A.,
538 P.T.S., S.R.L., J.D.F., S.L.E., J.S.L, B.W.D., G.C.T. KK.K; project administration: F.A.; funding
539 acquisition: F.A., J.M.S., P.T.S., G.C.T., KK.K. and S.R.L.

540 **Acknowledgements:** We thank the patients who donated samples and the Brisbane BioBank
541 for collection, annotation and provision of clinical samples for IHC studies. We acknowledge the
542 support of Metro North Hospital & Health Service in relation to collection of clinical subject data
543 and materials, and thank the QIMR Berghofer Flow cytometry, Microscopy and Histology
544 facilities for technical support.

545 References

- 546 1. Barros JC, Marshall CJ: Activation of either ERK1/2 or ERK5 MAP kinase pathways can
547 lead to disruption of the actin cytoskeleton. *J Cell Sci* 2005, 118:1663-1671.
- 548 2. Schramp M, Ying O, Kim TY, Martin GS: ERK5 promotes Src-induced podosome
549 formation by limiting Rho activation. *J Cell Biol* 2008, 181:1195-1210.
- 550 3. Sawhney RS, Liu W, Brattain MG: A novel role of ERK5 in integrin-mediated cell adhesion
551 and motility in cancer cells via Fak signaling. *J Cell Physiol* 2009, 219:152-161.
- 552 4. Wilhelmsen K, Mesa KR, Lucero J, Xu F, Hellman J: ERK5 protein promotes, whereas
553 MEK1 protein differentially regulates, the Toll-like receptor 2 protein-dependent activation
554 of human endothelial cells and monocytes. *J Biol Chem* 2012, 287:26478-26494.
- 555 5. Finegan KG, Perez-Madrigal D, Hitchin JR, Davies CC, Jordan AM, Tournier C: ERK5 is
556 a critical mediator of inflammation-driven cancer. *Cancer Res* 2015, 75:742-753.
- 557 6. Song C, Xu Q, Jiang K, Zhou G, Yu X, Wang L, Zhu Y, Fang L, Yu Z, Lee JD, et al:
558 Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.
559 *Oncotarget* 2015, 6:33279-33289.
- 560 7. Williams CA, Fernandez-Alonso R, Wang J, Toth R, Gray NS, Findlay GM: Erk5 Is a Key
561 Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity. *Cell Rep* 2016,
562 16:1820-1828.
- 563 8. Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME: Oncogenic
564 signaling of MEK5-ERK5. *Cancer Lett* 2017, 392:51-59.
- 565 9. Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N,
566 Pantazis P, Westphalen CB, Wang TC, Houchen CW: XMD8-92 inhibits pancreatic tumor
567 xenograft growth via a DCLK1-dependent mechanism. *Cancer Lett* 2014, 351:151-161.
- 568 10. Dai J, Wang T, Wang W, Zhang S, Liao Y, Chen J: Role of MAPK7 in cell proliferation and
569 metastasis in ovarian cancer. *International Journal of Clinical and Experimental*
570 *Pathology* 2015, 8:10444-10451.
- 571 11. Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray
572 NS, Esparis-Ogando A, et al: The mitogen-activated protein kinase ERK5 regulates the
573 development and growth of hepatocellular carcinoma. *Gut* 2015, 64:1454-1465.
- 574 12. Gavine PR, Wang M, Yu D, Hu E, Huang C, Xia J, Su X, Fan J, Zhang T, Ye Q, et al:
575 Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target
576 in squamous cell lung and esophageal carcinoma. *BMC Cancer* 2015, 15:454.
- 577 13. Pereira DM, Simoes AE, Gomes SE, Castro RE, Carvalho T, Rodrigues CM, Borralho PM:
578 MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil
579 through a p53-dependent mechanism. *Oncotarget* 2016, 7:34322-34340.
- 580 14. Xiong Y, Zhang L, Wang T: Phosphorylation of BMK1 induces prostatic carcinoma cell
581 proliferation by promoting entry into the S phase of the cell cycle. *Oncol Lett* 2016,
582 11:99-104.
- 583 15. Tusa I, Gagliardi S, Tubita A, Pandolfi S, Urso C, Borgognoni L, Wang J, Deng X, Gray
584 NS, Stecca B, Rovida E: ERK5 is activated by oncogenic BRAF and promotes melanoma
585 growth. *Oncogene* 2018, 37:2601-2614.

16. Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL: Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. *Oncogene* 2012, 31:3889-3900.
17. Castro NE, Lange CA: Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. *Breast Cancer Res* 2010, 12:R60.
18. Al-Ejeh F, Miranda M, Shi W, Simpson PT, Song S, Vargas AC, Saunus JM, Smart CE, Mariasegaram M, Wiegman AP, et al: Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. *Oncotarget* 2014, 5:3145-3158.
19. Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, et al: MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. *Mol Cancer Res* 2015, 13:934-943.
20. Miranda M, Rozali E, Khanna KK, Al-Ejeh F: MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments. *Oncoscience* 2015, 2:99-101.
21. Simoes AE, Rodrigues CM, Borralho PM: The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target. *Drug Discov Today* 2016, 21:1654-1663.
22. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, et al: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol* 2006, 7:R100.
23. Liu T, Winter M, Thierry B: Quasi-spherical microwells on superhydrophobic substrates for long term culture of multicellular spheroids and high throughput assays. *Biomaterials* 2014, 35:6060-6068.
24. Al-Ejeh F, Simpson PT, Saunus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, et al: Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. *Oncogenesis* 2014, 3:e100.
25. McCart Reed AE, Saunus JM, Ferguson K, Niland C, Simpson PT, Lakhani SR: The Brisbane Breast Bank. *Open Journal of Bioresources* 2018, 5:5.
26. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, et al: Metastatic progression of breast cancer: insights from 50 years of autopsies. *J Pathol* 2014, 232:23-31.
27. Kutasovic JR, McCart Reed AE, Males R, Sim S, Saunus JM, Dalley A, McEvoy CR, Dedina L, Miller G, Peyton S, et al: Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. *J Pathol Clin Res* 2019, 5:25-39.
28. Pavan S, Meyer-Schaller N, Diepenbruck M, Kalathur RKR, Saxena M, Christofori G: A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis. *Oncogene* 2018.
29. Yan C, Luo H, Lee JD, Abe J, Berk BC: Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. *J Biol Chem* 2001, 276:10870-10878.

30. McCaw BJ, Chow SY, Wong ES, Tan KL, Guo H, Guy GR: Identification and characterization of mErk5-T, a novel Erk5/Bmk1 splice variant. *Gene* 2005, 345:183-190.
31. Buschbeck M, Ullrich A: The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. *J Biol Chem* 2005, 280:2659-2667.
32. Madak-Erdogan Z, Ventrella R, Petry L, Katzenellenbogen BS: Novel roles for ERK5 and cofilin as critical mediators linking ERalpha-driven transcription, actin reorganization, and invasiveness in breast cancer. *Mol Cancer Res* 2014, 12:714-727.
33. Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y: Vimentin as a poor prognostic factor for triple-negative breast cancer. *J Cancer Res Clin Oncol* 2013, 139:739-746.
34. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Kawajiri H, Ogawa Y, Onoda N, Ishikawa T, Wakasa K, Hirakawa K: c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. *Br J Surg* 2013, 100:490-496.
35. Kondoh K, Terasawa K, Morimoto H, Nishida E: Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. *Mol Cell Biol* 2006, 26:1679-1690.
36. Gomez N, Erazo T, Lizcano JM: ERK5 and Cell Proliferation: Nuclear Localization Is What Matters. *Front Cell Dev Biol* 2016, 4:105.
37. Wrobel K, Zhao YC, Kulkoyluoglu E, Chen KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, et al: ERalpha-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization. *Mol Endocrinol* 2016, 30:1029-1045.
38. Erazo T, Moreno A, Ruiz-Babot G, Rodriguez-Asiain A, Morrice NA, Espadamala J, Bayascas JR, Gomez N, Lizcano JM: Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. *Mol Cell Biol* 2013, 33:1671-1686.
39. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. *Clin Cancer Res* 2006, 12:1533-1539.
40. Maimaiti Y, Liu Z, Tan J, Abudureyimu K, Huang B, Liu C, Guo Y, Wang C, Nie X, Zhou J, Huang T: Dephosphorylated cofilin expression is associated with poor prognosis in cases of human breast cancer: a tissue microarray analysis. *Onco Targets Ther* 2016, 9:6461-6466.
41. Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, et al: Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. *Breast Cancer Res* 2008, 10:R105.
42. Liu F, Zhang H, Song H: Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis. *Oncol Rep* 2017, 37:83-90.

43. Morikawa M, Koinuma D, Mizutani A, Kawasaki N, Holmborn K, Sundqvist A, Tsutsumi S, Watabe T, Aburatani H, Heldin CH, Miyazono K: BMP Sustains Embryonic Stem Cell Self-Renewal through Distinct Functions of Different Kruppel-like Factors. *Stem Cell Reports* 2016, 6:64-73.
44. Chen R, Yang Q, Lee JD: BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3beta signaling pathway. *Cancer Res* 2012, 72:1579-1587.
45. Liang Z, Xie W, Wu R, Geng H, Zhao L, Xie C, Li X, Huang C, Zhu J, Zhu M, et al: ERK5 negatively regulates tobacco smoke-induced pulmonary epithelial-mesenchymal transition. *Oncotarget* 2015, 6:19605-19618.
46. Zhai L, Ma C, Li W, Yang S, Liu Z: miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. *Mol Carcinog* 2016, 55:1990-2000.
47. Creighton CJ, Gibbons DL, Kurie JM: The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. *Cancer Manag Res* 2013, 5:187-195.
48. Rokavec M, Kaller M, Horst D, Hermeking H: Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression. *Sci Rep* 2017, 7:4687.

683 Figures

684

Figure 1: Active ERK5 changes subcellular localization during metastasis and cell migration.

(A) Spontaneous lung metastasis from primary tumors established from control (shNTC) or *ERK5*-depleted (shERK5#1 or shERK5#2) MDA-MB-231 cells. IHC for human vimentin was used to detect cancer cells. Representative images are shown at different magnifications; scale bars represent the lengths indicated. Refer to Figure S1A-C for complete metastasis models data. (B) Immunofluorescence (IF) with anti-pERK5 (Cell Signaling, green) and α-Tubulin (red) antibodies, and DAPI (blue) in control or *ERK5*-depleted MDA-MB-231 cells. Images shown are projections of Z-stacks from confocal microscopy (scale bar = 20 μm). Refer to **Additional File 1** for antibody specificity validation and IF in 4T1.2 and MCF7 cells. (C) Subcellular localization of pERK5 in primary MDA-MB-231 xenografts and matched lung metastasis. Representative IHC images are shown where elevated levels of extranuclear pERK5 was observed at the tumor border (invasive front), while the tumor core showed predominant nuclear pERK5 staining. Nuclear and extranuclear pERK5 staining patterns were also observed in matched lung metastases. (D) Localization of pERK5 in MDA231 and 4T1.2 cells during scratch wound-healing assays. Scratch wounds were generated in sub-confluent cultures and cells were fixed immediately (0h), 6 hours or 18 hours later to allow cell migration before IF staining. Representative images are shown (scale bar = 20 μm).

699

Figure 2: ERK5 isoforms, their activation and localization in breast cancer cells.

(A) Immunoblot of cytoplasmic and nuclear fractions from MDA-MB-231 (MDA231) and 4T1.2 cells with an anti-pERK5 antibody (Merck Millipore). Cell-fraction quality confirmed by the nuclear marker Lamin B1.

(B) Immunoprecipitation (IP) with another anti-pERK5 antibody (Cell Signaling) using cytoplasmic and nuclear fractions of MDA231 cells followed by immunoblotting (IB) with total ERK5 antibody. The blot (without stripping) was then re-probed with pERK1/2 antibody to exclude cross-reactivity.

(C) Schematic presentation of ERK5 domains and motifs of the transcripts expressed in breast cancer TCGA RNA-seq dataset (see Figure S2 for all transcripts).

(D) Pie charts depicting the percentage (in black) of cases with expression of ERK5 transcripts (z-score > 0).

(E) Comparison of the expression of ERK5 transcripts across the molecular (PAM50) and histological (IHC) subtypes of breast cancer (HR+: ER+/ PR+). Two-way ANOVA with Dunnett multiple comparisons test was used to compare the expression of each transcript (* P<0.05, ** P<0.01, **** P<0.0001)

Figure 3: ERK5 isoforms modulate pERK5 localization and cellular functions.

(A) IB and quantification ($n = 5$ independent blots) with total ERK5 antibody confirming the stable expression of cDNA encoding full length (isoform-1, Iso1), N-terminal truncated (isoform-2, Iso2), or C-terminal truncated (Isoform-3, Iso3) ERK5 in MCF7 cells (Figure S3D). (B) IF for pERK5 in the MCF7 lines expressing empty vector (EV) or each of the three ERK5 isoforms in the absence or presence of 10 nM estradiol (E2, 45 min). Representative images are shown (bar = 20 μ m, z-stacks); an independent set of images are shown in Figure S3E. (C) The ratio of extranuclear (ex.nuc) to nuclear (nuc) pERK5 fluorescence intensity was measured and compared after segmentation of cell compartments using CellProfiler ($n = 4$ per cell line, > 200 cells analyzed, one-way ANOVA, * $P < 0.05$ and ** $P < 0.01$). (D) Real time cell motility assays using the HoloMonitor[®] M4 system. Cell motility of 25-28 cells was tracked (left); inner and outer circles mark 50 and 100 μ m distance, respectively. Comparison of cell motility over time (right) of the four MCF7 cell lines showed that only isoform-3 expressing cells had a significant increase ($P < 0.001$, end-point comparison, one-way ANOVA). Cell migration assays, Transwell using CIM-plates, also showed increased cell migration of MCF7 cells expressing isoform-3 (Figure S3F). (E) Isoform-3 expressing MCF7 cells showed resistance to tamoxifen compared to other MCF7 lines (3 experiments, 6 replicates each).

796

797

798

799

800

801

802

803

804

805

806

807

808

809

Figure 4: ERK5 isoform-3 expression in cancers associates with EMT.

(A) The pan-cancer TCGA RNA-seq data (transcript expression RSEM-FPKM) was analyzed using the UCSC Xena platform (<http://xena.ucsc.edu/>) for the expression of the 18 *ERK5* transcripts (Table S4). The heatmap summarizes the expression of the 3 transcripts encoding full length ERK5, and the two transcripts encoding isoforms 2 and 3 across cancer types. Data shown are the average z-score (based on the average of all 18 *ERK5* transcripts across all cancers). (B) Association of *ERK5* isoforms expression with disease-specific survival (DSS) in the TCGA pan-cancer patients (n = 9,459; 9,009 with DSS information). The expression of three transcripts encoding full-length ERK5 (isoform-1) was combined (see Figure S4A). Isoform-1 and isoform-3 expression associated significantly with survival (log-rank test p-value shown), but not isoform-2. The combined co-expression of isoform-1 and isoform-3, depicted as a score and divided into five groups (Table S4), was more significantly associated with survival. (C) Association of the co-expression of ERK5 isoforms 1 and 3 (summarized into 5 groups) with EMT based on analysis of EMT signatures [47, 48] in the TCGA pan-cancer dataset (see Figure S4C, Table S5). One-way ANOVA was used for statistical comparisons (*** P<0.001, **** P<0.0001).

810

Figure 5: ERK5 isoform-3 expression in cancers associates with EMT.

(A) IF for pERK5 in the MCF7 lines expressing empty vector (EV) or ERK5 isoform-3 in the absence or presence of 10 ng/mL TGFβ. Representative images are shown (bar = 20 μm, z-stacks). The ratio of extranuclear (ex.nuc) to nuclear (nuc) pERK5 was measured as described in Figure 3. *** P < 0.001 one-way ANOVA. (B) RT-qPCR validation of genes selected from the RT² PCR array for human EMT panel carried out on MCF7-EV and MCF7-Iso3 cells (Table S6, Figure S5A). Data shown, average of two independent experiments, are the ratios of relative expression in comparison to MCF7-EV without TGFβ. * P < 0.05, ** P < 0.01, *** P < 0.001 one-way ANOVA. (C) Response of 3D cultures (spheroids) of MCF7-EV and MCF7-Iso3 cells to tamoxifen (10 μM). Representative images on day 7 are shown (scale bar = 0.2 mm). Graph shows the ratio of the size of the spheroids (area from imaging) compared to day 2 (n = 25 spheroids). Two-way ANOVA was used for statistical comparison (** P < 0.01, *** P < 0.001). Validation of the EMT genes marked by dots in panel B was done using cDNA prepared from the spheroids by RT-qPCR (refer to Figure S5D). (D-E) Representative IF of sections of spheroids stained with antibodies against CK19, CK5, E-cadherin, β-catenin and SOX2 (scale bar = 20 μm). Bar graphs in E are the average from two experiments with 3 spheroids each. * P < 0.05, ** P < 0.01, *** P < 0.001, one-way ANOVA.

825

Figure 6: ERK5 activation in primary tumors and metastases from breast cancer patients. (A) Staining of the follow-up cohort (QFU, n = 393) for pERK5 (Cell Signaling antibody). Representative images of staining patterns are shown. Nuclear staining was scored as negative (N0), positive (N1) or strongly positive (N2); membrane staining as negative (M0), < 50% (M1) or > 50% (M2) of tumor cells with continuous staining; cytoplasmic staining as negative or positive (C0 or C1). Given the strong correlation, the membrane and cytoplasmic staining (extranuclear) were combined into four groups; MC0: negative for both, M/C+: positive for either, MC1: cytoplasmic positive and <50% continuous membrane staining; MC2: cytoplasmic positive and >50% continuous membrane staining. The 10-year overall survival was significantly stratified based on (B) extranuclear or (C) nuclear staining. Hazard ratios (HR) and p values (log-rank test) are shown. Refer to Figure S6A-B for supporting data. (D) As the nuclear and extranuclear pERK5 staining were not mutually exclusive (see Figure S6C), we consolidated these patterns to four type; Cat-A: negative for extranuclear and nuclear staining, Cat-B: positive nuclear staining without strong extranuclear staining; Cat-C: strong nuclear staining without strong extranuclear staining; Cat-D: strongly positive for extranuclear pERK5 irrespective of nuclear staining. Cat-D associated with aggressive features in the QFU cohort. (E-G) pERK5 staining in primary metastatic tumors (MBC) and metastases (Mets) was similarly carried out (MBC n = 70, Mets. n = 215, Table S8, Figure S6E). Chi-square (χ^2) test was used for statistical comparisons.

Additional File 1: Testing the specificity of the pERK5 antibody from Cell Signaling

Immunoprecipitation (IP) and immunoblotting (IB) as well as immunofluorescence were used to evaluate the specificity of the anti-pERK5 antibody from Cell Signaling Technology (product #3371). For this evaluation we used another antibody against pERK5 from Merck Millipore (product #07-507) and antibody against total-ERK5 (tERK5) from Cell Signaling (product #3372).

It should be noted that the pERK5 antibody from Cell Signaling (pERK5 CS) does not perform by direct IB to detect endogenous or exogenously expressed ERK5. The antibody against pERK5 from Merck Millipore (pERK5 MM) performs in blotting but is suboptimal for IF and immunohistochemistry (Data not shown).

We first carried out IP with the pERK5 (CS) from MDA-MB-231 expressing non-target control (NTC) or *ERK5*-specific (sh2) shRNAs followed by IB with tERK5 (CS) antibody **Fig.A** or with pERK5 (MM) antibody **Fig.B**. Multiple bands were observed in control cells using either pERK5 or tERK5 antibodies but were reduced in cells with *ERK5* shRNA, indicating that these bands are indeed pERK5 isoforms. In both experiments in **Fig.A&B**, we re-probed the blots without any stripping with anti-pERK1/2 antibody (Cell Signaling) to test if the pERK5 antibody also precipitates pERK1/2. As shown in both **Fig.A&B**, IB with pERK1/2 detected pERK1/2 in the input but not after IP with the pERK5 (CS) antibody.

This confirmed that the three bands observed are indeed pERK5 which were specifically immunoprecipitated by the pERK5 (CS) antibody because:

1. bands from IP with pERK5 (CS) were detected by tERK5 antibody (**Fig.A**)
2. bands from IP with pERK5 (CS) were detected by pERK5 (MM) antibody (**Fig.B**)
3. bands from IP with pERK5 (CS) reduced with shRNA knockdown of *ERK5* (**Fig.A&B**)
4. re-probing (without any stripping)* with pERK1/2 antibody did not detect bands corresponding to pERK1/2 after IP with pERK5 (CS).

We further confirmed that IP with either pERK5 (CS) or pERK5 (MM) antibodies precipitated different forms of *ERK5* (**Fig.C**) because they were:

5. detected by the total *ERK5* antibody, tERK5 (CS) antibody, and
6. reduced by the *ERK5*-specific shRNA (sh2).

Moreover, we also tested if the *ERK5*-specific shRNA affected the expression of *ERK1/2* or p38. As shown **Fig.D**, total *ERK1/2* (tERK1/2) or p38 proteins were not affected in *ERK5*-depleted MDA-MB-231 cells. However, the phosphorylation levels (pERK1/2 and p-p38) was reduced most likely due to cell signalling effect in the MAPK signalling pathways. This confirms that:

7. bands observed in **Fig.A-C** are isoforms of *ERK5* and that *ERK5* shRNA is specific (**Fig.D**).

Finally, we carried out IF with the human MDA-MB-231 and the mouse 4T1.2 cells (TNBC lines) and the human MCF7 cell line (ER+). *ERK5* was depleted in the MDA-MB-231 and 4T1.2 cells using two specific shRNAs in comparison to non-target control (NTC), and IF was carried out in comparison to rabbit IgG control antibody (**Fig.E**). The results show that:

8. IF with pERK5 (CS) antibody is specific (produced signal) compared to equimolar amount of rIgG
9. IF with pERK5 (CS) antibody is specific to *ERK5* because signal was diminished by *ERK5* shRNA
10. pERK5 shows different cell localization in TNBC cells compared to the non-TNBC MCF7 cells

* Re-probing was done by washing the blots with PBS/T followed by blocking, incubation overnight with pERK1/2 antibody, followed by washing and incubation with secondary antibody-HRP, followed by washing then detection (i.e. 24-36 hours after detection of *ERK5* bands, hence reduced detection of *ERK5* bands in the re-probed blots).

Fig: Testing the specificity of the pERK5 antibody from Cell Signaling.

(A-B) MDA-MB-231 cells expressing non-target control (shNTC) or *ERK5*-specific (sh2) shNRA were lysed using RIPA buffer after washing cell cultures with PBS (no trypsin use). Immunoprecipitation (IP) of pERK5 (TEY motif phosphorylation at the T218/Y220 residues) was carried out using pERK5 antibody from Cell Signaling Technologies [pERK5 (CS)] followed by immunoblots (IB) with antibody against total ERK5 protein [tERK5 (CS)] in panel A or another antibody against pERK5 from Merck Millipore [pERK5 (MM)] in panel B. In both experiments, membranes were washed extensively before re-probing (without any stripping) with an antibody against pERK1/2. (C) IP from MDA-MB-231 cells using either pERK5 (CS) or pERK5 (MM) antibodies followed by IB using the tERK5 (CS) antibody. All experiments used IP with beads conjugated with control rabbit IgG was used as control. (D) MDA-MB-231 cells were analyzed for the levels of total and phosphorylated forms of ERK1/2 and p38. (E) Immunofluorescence with pERK5 (CS) antibody in comparison to matching concentration (15 µg/mL) of non-specific rabbit IgG (rlgG) antibody. Cells were also stained for α-Tubulin (cytoskeleton, red) and DAPI (nuclei, blue). Images shown are projections of Z-stacks from confocal microscopy (scale bar = 20 µm).

842 Supplementary Figures

843

844 Figure S1: Supporting data for the spontaneous metastasis mouse models.

845 (A) Growth of primary MDA-MB-231 (MDA231) and 4T1.2 control (shNTC) and *ERK5*-depleted (shERK5#1 or
846 shERK5#2) tumors based on caliper measurement confirming similar tumor growth rates. (B) Knockdown of *ERK5*
847 was confirmed by immunoblotting using lysates prepared from resected MDA231 tumors (at 250 mm³ volume). Data
848 shown are representative results from three independent mice (m1-m3). (C) MDA231 and 4T1.2 tumors (shNTC
849 control and *ERK5*-depleted) were resected from mice at 250 mm³ or 150 mm³ volume, respectively, to follow
850 metastasis by bioluminescence imaging. Representative images are shown, and metastasis-free survival was
851 compared by log-rank test using data combined from independent experiments (MDA231 model: three experiments
852 with total $n = 15$ mice/group, 4T1.2 model: two experiments with total $n = 10$ mice/group).

853

854 **Figure S2:** Supporting data for the expression of ERK5 splice variants in breast cancer tissue
855 from patients.

856 Expression of *ERK5* transcripts in the TCGA breast cancer RNA-seq dataset. Schematic presentation of ERK5
857 domains and motifs across all annotated transcripts (Ensembl, maroon: protein-coding, grey: processed or
858 intron-retaining transcripts) which we mapped in the RNA-Seq data from the TCGA BC dataset. Transcripts
859 *MAPK7-208* and *MAPK7-209* retain introns which results in premature stop codons becoming in frame for
860 translation (* denote the location of the premature stop in the ERK5 protein). The expression of the transcripts was
861 compared according to the PAM50 or IHC (ER, PR and HER2) subtypes. One-way ANOVA with Dunnett multiple
862 comparisons test was used to compare the expression of each transcript across groups (** $P < 0.01$, *** $P < 0.001$,
863 **** $P < 0.0001$).

877

878 **Figure S4:** Supporting data for *ERK5* isoforms expression across cancer types and association
888 with EMT.

889 (A) The pan-cancer TCGA RNA-seq data (transcript expression RSEM-FPKM) was analyzed using the UCSC Xena
890 platform (<http://xena.ucsc.edu/>) for the expression of the 18 *ERK5* transcripts (Table S4). Stratification of disease-
891 specific survival (DSS) according to the expression of transcripts encoding full length *ERK5* (isoform-1) using
892 quartile groups (1: first/lower quartile, 2: second quartile, 3: third quartile, 4: fourth/upper quartile). For isoform-1
893 transcript variants 1 and 3 (v1 and v3), only the upper quartile group showed significantly lower survival (****
894 P<0.0001). Thus, patients were classified according to the expression of these transcripts in the lower panels as 1:
895 lower than upper quartile vs. 2: higher than upper quartile. For isoform-1 transcript variant 4 (v4), the second and
896 third quartiles were not significantly different from each other but were significantly different from lower and upper
897 quartiles (** P=0.0074). As shown in the lower panel, patients were classified based on the expression of isoform-1
898 transcript v4 as 1: lower quartile, 2: second and third quartiles, 3: upper quartile. (B) Correlation of two published
899 EMT signatures [30,31] were used in combination to calculate EMT scores. The Epithelial score (E.Score) and the
900 Mesenchymal score (M.Score) were calculated as the average expression of the genes associated with epithelial
901 and mesenchymal states, respectively. These scores were compared across the 5 groups of the co-expression
902 levels of *ERK5* isoforms 1 and 3. * P<0.05, ** P<0.01, one-way ANOVA. (C) High co-expression of isoforms 1 and
903 3 (red) was not restricted to a cancer type and evident in several cancers in the TCGA. All cancer cases in all cancer
904 types are presented; each case is colored according to its value for the co-expression of isoforms 1 and 3.

905

906 **Figure S5: Supporting data for ERK5 isoform-3 role in epithelial-mesenchymal transition.**

907 (A) RT² PCR array for human EMT panel on MCF7-EV (control) and MCF7-Iso3 cells in the absence of presence of
908 TGFβ (10 ng/mL) carried out on technical duplicates (Table S5). The heatmap summarizes the relative expression
909 of the genes as the ratio to MCF7-EV without TGFβ. Genes marked with dots were selected for validation in
910 Figure 6B. (B) The expression of genes from RT² PCR array for human EMT panel in the Pan-Cancer TCGA dataset
911 grouped as per the co-expression of isoforms 1 and 3. The Heatmap shows the expression (Z-score) of each gene
912 across the 5 groups and one-way ANOVA was used for statistical comparison of each gene across the different
913 groups. (C) RT-PCR validation of selected EMT genes, which were driven by isoform-3 specifically, using cDNA
914 prepared from MCF7 spheroids (25 spheres per group). * P<0.05, ** P<0.01, *** P<0.001 one-way ANOVA.
915 (D) Model for a dual role of ERK5 in BC pathobiology, which may be mediated by the shorter ERK5 isoform-3. The
916 expression of isoform-3 would increase the extranuclear pERK5 to facilitate EMT and the migration of cells from the
917 primary tumor to distant organs (e.g. brain). Through cycles of invasion and expansion, thus shuttling of pERK5,
918 overt metastases are formed.

919

920 **Figure S6: Supporting data for pERK5 staining in breast cancer patients.**

921 (A) IHC with pERK5 antibody (from Cell Signaling, 5x magnification) in the normal MCF10A cells and control
922 (shNTC) and *ERK5*-depleted (shERK5#2) cells. (B) Complete survival follow-up of breast cancer patients in the
923 Follow Up (QFU) cohort of sporadic breast cancer cases and stratification by nuclear (left) and extranuclear (right)
924 pERK5 staining. (C) Stratification of overall survival based on nuclear pERK5 staining in ER+ (left) and ER- (right)
925 breast cancer. (D) The nuclear and extranuclear pERK5 staining were not mutually exclusive, thus were re-grouped
926 as negative for extranuclear (Ex) and nuclear (N) pERK5 (ExN0/N0, Cat-A), positive or strongly positive for nuclear
927 pERK5 in the absence of strong extranuclear pERK5 (ExN0/N1 - Cat-B or ExN0/N2 - Cat-C, respectively), or
928 strongly positive for extranuclear pERK5 irrespective of nuclear staining (ExN1/Nx, Cat-D). These groups had
929 significantly different overall survival (log-rank test). (E) pERK5 staining in primary metastatic tumors (Pri) and
930 metastases (Mets) was similarly carried out (Pri. n = 70, Mets. n = 215; 60 Pri. matched with 204 Mets, Tables S8).
931 The pERK5 staining in each of the three cellular compartments (cytoplasm, nucleus and membrane) was compared
932 with the metastasis cohorts and with the QFU cohort (Chi-square test, GraphPad Prism).